261 related articles for article (PubMed ID: 26563750)
1. Heterogeneity of the Mac-1 expression on peripheral blood neutrophils in patients with different types of epithelial ovarian cancer.
Bednarska K; Klink M; Wilczyński JR; Szyłło K; Malinowski A; Sułowska Z; Nowak M
Immunobiology; 2016 Feb; 221(2):323-32. PubMed ID: 26563750
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
3. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with epithelial ovarian cancer.
Giebel S; Boratyn-Nowicka A; Karabon L; Jedynak A; Pamula-Pilat J; Tecza K; Kula D; Kowal M; Frydecka I; Grzybowska E
Hum Immunol; 2014 Jun; 75(6):508-13. PubMed ID: 24755350
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
5. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
6. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
7. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
[TBL] [Abstract][Full Text] [Related]
9. Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
Ma M; Yu N
Tohoku J Exp Med; 2017 Mar; 241(3):239-247. PubMed ID: 28344213
[TBL] [Abstract][Full Text] [Related]
10. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
11. Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer.
Bednarska K; Król E; Głowacka E; Romanowicz H; Szyłło K; Klink M; Sułowska Z; Nowak M
Medicine (Baltimore); 2018 Mar; 97(12):e0180. PubMed ID: 29561432
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-130b functions as a tumor suppressor by regulating RUNX3 in epithelial ovarian cancer.
Paudel D; Zhou W; Ouyang Y; Dong S; Huang Q; Giri R; Wang J; Tong X
Gene; 2016 Jul; 586(1):48-55. PubMed ID: 27048832
[TBL] [Abstract][Full Text] [Related]
13. ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
Jung M; Gao J; Cheung L; Bongers A; Somers K; Clifton M; Ramsay EE; Russell AJ; Valli E; Gifford AJ; George J; Kennedy CJ; Wakefield MJ; Topp M; Ho GY; ; Scott CL; Bowtell DD; deFazio A; Norris MD; Haber M; Henderson MJ
Int J Cancer; 2020 Oct; 147(8):2225-2238. PubMed ID: 32277480
[TBL] [Abstract][Full Text] [Related]
14. Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer.
Gamzatova Z; Villabona L; Dahlgren L; Dalianis T; Nillson B; Bergfeldt K; Masucci GV
Gynecol Oncol; 2006 Oct; 103(1):145-50. PubMed ID: 16542716
[TBL] [Abstract][Full Text] [Related]
15. [Ovarian cancer--modern approach to its origin and histogenesis].
Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2012 Jun; 83(6):454-7. PubMed ID: 22880466
[TBL] [Abstract][Full Text] [Related]
16. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
[TBL] [Abstract][Full Text] [Related]
17. Relations between GPR4 expression, microvascular density (MVD) and clinical pathological characteristics of patients with epithelial ovarian carcinoma (EOC).
Ren J; Jin W; Gao YE; Zhang Y; Zhang X; Zhao D; Ma H; Li Z; Wang J; Xiao L; Liu R; Chen Y; Qian J; Niu L; Wei H; Liu Y
Curr Pharm Des; 2014; 20(11):1904-16. PubMed ID: 23888957
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.
Feigenberg T; Clarke B; Virtanen C; Plotkin A; Letarte M; Rosen B; Bernardini MQ; Kollara A; Brown TJ; Murphy KJ
Biomed Res Int; 2014; 2014():367103. PubMed ID: 24982872
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
20. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
